Biosimilars
Pfizer and Biocon Partner to Commercialize Biosimilar Insulin Products
New Biosimilar Insulin May Provide Cheaper Alternative to Lantus — How Does it Compare?
Clinical trial currently enrolling for type 2 diabetes – find out if you qualify for this study.
FDA Approves New Insulin Glargine Basaglar – The First “Biosimilar” Insulin in the US
Will this drug be cheaper than Lantus and other insulins?